Skip to main content
Terug
TVTX logo

Travere Therapeutics, Inc.

Datakwaliteit: 100%
TVTX
NASDAQ Healthcare Biotechnology
€ 26,79
▼ € 0,96 (-3,46%)
Marktkapitalisatie: 2,47B
Dagbereik
€ 26,49 € 27,31
52-Weeksbereik
€ 12,91 € 42,13
Volume
833.782
50D / 200D Gem.
€ 29,58 / € 25,90
Vorige Slotkoers
€ 27,75

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -49,2 0,3
P/B 21,5 2,9
ROE % -57,8 3,7
Net Margin % -10,2 3,8
Rev Growth 5Y % 38,9 10,0
D/E 2,9 0,2

Koersdoel Analisten

Hold
€ 49,00 +82.9%
Forward K/W
73,6
Forward WPA
€ 0,38
WPA Groei (sch.)
+0,0%
Omzet Sch.
700 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 5,07
€ 3,97 – € 6,32
1,5 B 2
FY2029 € 4,07
€ 3,19 – € 5,08
1,3 B 4
FY2028 € 3,41
€ 2,02 – € 5,75
1,1 B 6

Belangrijkste Punten

Revenue grew 38,90% annually over 5 years — strong growth
Debt/Equity of 2,86 — high leverage
Generating 37,78M in free cash flow
PEG of 0,79 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 71,55%
Capital efficient — spends only 0,00% of revenue on capex

Groei

Revenue Growth (5Y)
38,90%
Revenue (1Y)110,45%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-57,80%
ROIC-10,62%
Net Margin-10,24%
Op. Margin-12,80%

Veiligheid

Debt / Equity
2,86
Current Ratio2,74
Interest Coverage-5,85

Waardering

P/E Ratio
-49,17
P/B Ratio21,52
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 110,45% Revenue Growth (3Y) 83,81%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 38,90% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 490,73M Net Income (TTM) -50,26M
ROE -57,80% ROA -8,30%
Gross Margin 85,51% Operating Margin -12,80%
Net Margin -10,24% Free Cash Flow (TTM) 37,78M
ROIC -10,62% FCF Growth (3Y) N/A
Safety
Debt / Equity 2,86 Current Ratio 2,74
Interest Coverage -5,85 Dividend Yield 0,00%
Valuation
P/E Ratio -49,17 P/B Ratio 21,52
P/S Ratio 5,04 PEG Ratio 0,79
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,47B Enterprise Value 2,71B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 490,73M 233,18M 145,24M 109,46M 131,84M
Net Income -50,26M -321,55M -111,40M -278,48M -180,09M
EPS (Diluted) -0,56 -4,08 -1,50 -4,37 -3,01
Gross Profit 419,65M 225,43M 133,79M 105,04M 128,02M
Operating Income -62,82M -323,83M -388,14M -319,81M -199,43M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 605,19M 594,13M 788,91M 672,59M 776,63M
Total Liabilities 490,36M 535,05M 588,10M 629,73M 474,52M
Shareholders' Equity 114,83M 59,08M 200,81M 42,85M 302,11M
Total Debt 328,73M 401,58M 404,78M 407,49M 261,99M
Cash & Equivalents 93,04M 58,54M 58,18M 61,69M 165,75M
Current Assets 437,57M 416,70M 616,78M 486,44M 582,83M
Current Liabilities 159,90M 200,75M 177,91M 142,16M 124,09M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#1 of 146
91

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026